​

Intellia Therapeutics (NTLA) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

NTLA Stock Forecast

Intellia Therapeutics (NTLA) stock forecast, based on 14 Wall Street analysts, predicts a 12-month average price target of $44.00, with a high of $60.00 and a low of $18.00. This represents a 334.78% increase from the last price of $10.12.

$10 $20 $30 $40 $50 $60 High: $60 Avg: $44 Low: $18 Last Closed Price: $10.12

NTLA Stock Rating

Intellia Therapeutics stock's rating consensus is Buy, based on 14 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 14 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 14 0 14 Strong Sell Sell Hold Buy Strong Buy

NTLA Forecast vs Benchmarks

TypeNameUpside
StockIntellia Therapeutics334.78%
SectorHealthcare Stocks 25.20%
IndustryBiotech Stocks 63.35%

Price Target Trends

1M3M12M
# Anlaysts-16
Avg Price Target-$60.00$51.00
Last Closing Price$10.12$10.12$10.12
Upside/Downside-492.89%403.95%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jan, 255187--30
Dec, 246186--30
Nov, 246186--30
Oct, 248186--32
Sep, 248186--32
Latest Price Target by Analysts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Nov 11, 2024Jay OlsonOppenheimer$60.00$17.16249.65%492.89%
Oct 24, 2024Jack AllenRobert W. Baird$18.00$15.8513.56%77.87%
Aug 09, 2024Luca IssiRBC Capital$54.00$22.38141.29%433.60%
Jun 24, 2024Dae Gon HaStifel Nicolaus$80.00$25.22217.21%690.51%
Jun 24, 2024Jack AllenRobert W. Baird$24.00$26.00-7.69%137.15%
May 10, 2024Kostas BiliourisBMO Capital$70.00$24.84181.80%591.70%
Feb 01, 2023Cantor Fitzgerald$67.00$42.4457.87%562.06%
Jan 04, 2023Wells Fargo$120.00$36.64227.51%1085.77%
Dec 06, 2022Credit Suisse$88.00$40.03119.84%769.57%
Dec 02, 2022Leerink Partners$86.00$45.8087.77%749.80%
Latest Upgrade/Downgrade by Analysts
DateCompanyPrevious RatingNew RatingRating Change
Nov 11, 2024OppenheimerOutperformOutperformhold
Oct 16, 2024BMO CapitalOutperformOutperformhold
Sep 11, 2024RBC CapitalBuyBuyhold
Aug 12, 2024RBC CapitalBuyBuyhold
Aug 09, 2024RBC CapitalOutperformOutperformhold
Jun 26, 2024BMO CapitalOutperformOutperformhold
Jun 24, 2024WedbushBuyBuyhold
Jun 04, 2024WedbushNeutralNeutralhold
Jun 03, 2024Cowen & Co.BuyBuyhold
Jun 03, 2024CitigroupNeutralNeutralhold

Financial Forecast

EPS Forecast

$-25 $-14 $-3 $8 $19 $30 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-2.24$-3.66$-6.37$-5.42-----
Avg Forecast$-2.28$-3.60$-6.16$-5.44$-5.31$-5.13$-4.98$-2.60$1.51
High Forecast$-5.30$-8.38$-21.52$-5.71$-5.63$-6.57$-7.02$-9.26$-0.20
Low Forecast$-0.55$-0.87$0.85$-4.98$-4.87$-4.04$-3.14$27.79$5.39
Surprise %-1.75%1.67%3.41%-0.37%-----

Revenue Forecast

$0 $800M $2B $2B $3B $4B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$57.99M$33.05M$52.12M$36.27M-----
Avg Forecast$66.73M$29.16M$51.90M$50.66M$53.93M$53.11M$39.23M$452.34M$1.25B
High Forecast$27.73M$12.12M$6.49M$37.80M$45.78M$6.78M$5.01M$451.97M$159.15M
Low Forecast$134.73M$58.87M$151.42M$79.15M$63.58M$158.30M$116.94M$452.71M$3.71B
Surprise %-13.09%13.36%0.43%-28.39%-----

Net Income Forecast

$-1B $-300M $400M $1B $2B $3B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-125.57M$-259.72M$-490.21M$-481.19M-----
Avg Forecast$-123.01M$-230.77M$-354.34M$-481.19M$-466.19M$-527.95M$-559.65M$-271.07M$133.85M
High Forecast$-147.61M$-276.92M$-425.21M$-577.43M$-500.12M$-583.20M$-622.89M$-821.94M$-17.93M
Low Forecast$-98.41M$-184.61M$-283.48M$-384.95M$-432.25M$-358.27M$-278.87M$2.47B$478.51M
Surprise %2.08%12.55%38.34%------

NTLA Forecast FAQ

Is Intellia Therapeutics stock a buy?

Intellia Therapeutics stock has a consensus rating of Buy, based on 14 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 14 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Intellia Therapeutics is a favorable investment for most analysts.

What is Intellia Therapeutics's price target?

Intellia Therapeutics's price target, set by 14 Wall Street analysts, averages $44 over the next 12 months. The price target range spans from $18 at the low end to $60 at the high end, suggesting a potential 334.78% change from the previous close price of $10.12.

How does Intellia Therapeutics stock forecast compare to the average forecast of its sector, industry, and investment themes?

Intellia Therapeutics stock forecast shows a 334.78% upside, outperforming the average forecast for the healthcare stocks sector (25.20%) and outperforming the biotech stocks industry (63.35%).

What is the breakdown of analyst ratings for Intellia Therapeutics over the past three months?

  • January 2025: 16.67% Strong Buy, 60.00% Buy, 23.33% Hold, 0% Sell, 0% Strong Sell.
  • December 2024: 20.00% Strong Buy, 60.00% Buy, 20.00% Hold, 0% Sell, 0% Strong Sell.
  • November 2024: 20.00% Strong Buy, 60.00% Buy, 20.00% Hold, 0% Sell, 0% Strong Sell.

What is Intellia Therapeutics’s EPS forecast?

Intellia Therapeutics's average annual EPS forecast for its fiscal year ending in December is -5.31 for 2024, a -2.03% decrease from the reported $-5.42 in 2023. The prediction for 2025 is $-5.13, $-4.98 for 2026, $-2.6 for 2027, and $1.51 for 2028.

What is Intellia Therapeutics’s revenue forecast?

Intellia Therapeutics's average annual revenue forecast for its fiscal year ending in December is $53.93M for 2024, a 48.67% increase from the reported $36.28M in 2023. The forecast for 2025 is $53.11M, $39.23M for 2026, $452.34M for 2027, and $1.25B for 2028.

What is Intellia Therapeutics’s net income forecast?

For its fiscal year ending in December, Intellia Therapeutics's average annual net income forecast is $-466M for 2024, reflecting a -3.12% decrease from the reported $-481M in 2023. The projection for 2025 is $-528M, $-560M for 2026, $-271M for 2027, and $133.85M for 2028.